PHRRF Stock Chart & Stats
$0.04
<$0.01(28.21%)
At close: 4:00 PM EDT
$0.04
<$0.01(28.21%)
Day’s Range― - ―
52-Week Range$0.03 - $0.12
Previous CloseN/A
Volume58.18K
Average Volume (3M)66.41K
Market Cap
$3.58M
Enterprise Value$9.70M
Total Cash (Recent Filing)$921.54K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding91,019,066
10 Day Avg. Volume35,208
30 Day Avg. Volume66,414
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)8.91
Price to Sales (P/S)0.00
P/FCF Ratio-11.26
Enterprise Value/Market Cap2.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$59.52M
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of total debt reduces refinancing pressure and interest obligations, giving PharmaTher greater flexibility while it advances its ketamine-focused programs. Low leverage also limits the risk that financial distress could disrupt development spending or weaken the company’s negotiating position.
Narrowing Net LossesThe substantial reduction in annual losses indicates improved cost control and a more disciplined operating profile, even though the company remains unprofitable. If maintained, this trajectory can extend its financial runway and reduce the amount of capital required to support ongoing development activities.
Lower Operating Cash BurnA materially smaller operating cash deficit suggests that spending has become more controlled as the business progresses through its early development stage. Lower cash consumption can preserve resources for clinical, regulatory, and commercialization work, although the company has not yet reached self-funding.
Bears Say
Pre-Revenue BusinessWith no reported revenue base, PharmaTher has not yet demonstrated commercial demand or recurring cash generation from its ketamine-based therapeutics. This leaves future financial performance dependent on successful development and commercialization, making earnings quality and operating sustainability weak over the medium term.
Persistent Cash BurnPersistent negative operating and free cash flow means the company continues to consume cash to fund operations rather than internally financing its programs. Unless commercialization changes this pattern, ongoing development may require external funding, limiting strategic flexibility and increasing dependence on capital availability.
Shrinking Equity BaseThe steep erosion of stockholders’ equity shows that cumulative losses or capital outflows have substantially reduced the company’s financial base. A smaller equity cushion provides less capacity to absorb setbacks, support long development timelines, or fund growth without further shareholder financing.
PharmaTher Holdings Ltd News
PHRRF FAQ
What was PharmaTher Holdings Ltd’s price range in the past 12 months?
PharmaTher Holdings Ltd lowest stock price was $0.03 and its highest was $0.12 in the past 12 months.
What is PharmaTher Holdings Ltd’s market cap?
PharmaTher Holdings Ltd’s market cap is $3.58M.
When is PharmaTher Holdings Ltd’s upcoming earnings report date?
PharmaTher Holdings Ltd’s upcoming earnings report date is Oct 28, 2026 which is in 3 days.
How were PharmaTher Holdings Ltd’s earnings last quarter?
PharmaTher Holdings Ltd released its earnings results on Jan 30, 2026. The company reported -$0.002 earnings per share for the quarter.
Is PharmaTher Holdings Ltd overvalued?
According to Wall Street analysts PharmaTher Holdings Ltd’s price is currently Overvalued.
Does PharmaTher Holdings Ltd pay dividends?
PharmaTher Holdings Ltd does not currently pay dividends.
What is PharmaTher Holdings Ltd’s EPS estimate?
PharmaTher Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaTher Holdings Ltd have?
PharmaTher Holdings Ltd has 91,019,066 shares outstanding.
What happened to PharmaTher Holdings Ltd’s price movement after its last earnings report?
PharmaTher Holdings Ltd reported an EPS of -$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PharmaTher Holdings Ltd?
Currently, no hedge funds are holding shares in PHRRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration techniques for psychedelics to treat a range of conditions including mental health disorders, neurological ailments, and chronic pain. A key asset in its development portfolio is an intravenous ketamine injection, currently undergoing Phase II and III clinical evaluations targeting indications such as Parkinson's disease, anesthesia/sedation, and amyotrophic lateral sclerosis (ALS). The company's pipeline further features a Ketamine Patch, which is progressing through Phase I and II clinical trials for the treatment of depression, various mental health conditions, complex regional pain syndrome (CRPS), and other pain-related disorders. Additionally, a Ketamine Pump is undergoing Phase II clinical assessment for use in mental health, pain management, and surgical/procedural settings. Beyond these, PharmaTher is actively developing PHARMAPATCH, an innovative microneedle patch designed for psychedelic drug delivery. The company has established strategic collaboration agreements with several partners, including LTS Lohmann Therapie-Systeme AG for developing a ketamine microneedle patch; Alcami Corporation for the advancement of ketamine injectables and infusions; BioRAE, Inc. for the development of ketamine pump technology; Revive Therapeutics Ltd. to develop a psilocybin microneedle patch; and Gesval S.A. for the development of patented continuous-flow process technology for synthesizing ketamine and its analogs. PharmaTher is also internally dedicated to creating its own proprietary wearable ketamine delivery system, intended for addressing mental health, neurological, and pain conditions. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Technical Analysis
COSCIENS Biopharma
―
Kane Biotech
―
BetterLife Pharma
―
BioVaxys Technology
―
Marvel Biosciences Corp
―
Ownership Overview
0.44% Insiders
<0.01% Other Institutional Investors
99.56% Public Companies and
Individual Investors